Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling

Prasad R. Konkalmatt, Feng Wang, Bryan A. Piras, Yaqin Xu, Daniel M. O'Connor, Ronald J. Beyers, Frederick H. Epstein, Brian H. Annex, John A. Hossack, Brent A. French

Research output: Contribution to journalArticle

Abstract

Background: Adeno-associated virus serotype 9 (AAV9) vectors provide efficient and uniform gene expression to normal myocardium following systemic administration, with kinetics that approach steady-state within 2-3 weeks. However, as a result of the delayed onset of gene expression, AAV vectors have not previously been administered intravenously after reperfusion for post-infarct gene therapy applications. The present study evaluated the therapeutic potential of post-myocardial infarction gene delivery using intravenous AAV9. Methods: AAV9 vectors expressing firefly luciferase, enhanced green fluorescent protein (eGFP) or extracellular superoxide dismutase genes from the cardiac troponin-T (cTnT) promoter (AcTnTLuc, AcTnTeGFP, AcTnTEcSOD) were employed. AcTnTLuc was administered intravenously at 10 min and at 1, 2 and 3 days post-ischemia/reperfusion (IR), and the kinetics of luciferase expression were assessed with bioluminescence imaging. AcTnTeGFP was used to evaluate the distribution of eGFP expression. High-resolution echocardiography was used to evaluate the effects of AcTnTEcSOD on left ventricular (LV) remodeling when injected 10 min post-IR. Results: Compared to sham animals, luciferase expression at 2 days after vector administration was elevated by four-, 24-, 210- and 213-fold in groups injected at 10 min, 1 day, 2 days and 3 days post-IR, respectively. The expression of cTnT-driven eGFP was strongest in cardiomyocytes bordering the infarct zone. In the efficacy study of EcSOD, post-infarct LV end-systolic and end-diastolic volumes at days 14 and 28 were significantly smaller in the EcSOD group compared to the control. Conclusions: Systemic administration of AAV9 vectors after IR both elevates and accelerates gene expression that preferentially targets cardiomyocytes in the border zone with pharmacodynamics suitable for the attenuation of LV remodeling.

Original languageEnglish (US)
Pages (from-to)609-620
Number of pages12
JournalJournal of Gene Medicine
Volume14
Issue number9-10
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Dependovirus
Ventricular Remodeling
Cardiac Myocytes
Reperfusion
Ischemia
Troponin T
Luciferases
Gene Expression
Firefly Luciferases
Genetic Therapy
Genes
Superoxide Dismutase
Echocardiography
Myocardium
Myocardial Infarction
Serogroup
enhanced green fluorescent protein

Keywords

  • AAV
  • Cardiac gene therapy
  • Ischemia and reperfusion injury
  • LV remodeling
  • Post myocardial infarction gene delivery

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Drug Discovery
  • Genetics(clinical)

Cite this

Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling. / Konkalmatt, Prasad R.; Wang, Feng; Piras, Bryan A.; Xu, Yaqin; O'Connor, Daniel M.; Beyers, Ronald J.; Epstein, Frederick H.; Annex, Brian H.; Hossack, John A.; French, Brent A.

In: Journal of Gene Medicine, Vol. 14, No. 9-10, 01.09.2012, p. 609-620.

Research output: Contribution to journalArticle

Konkalmatt, Prasad R. ; Wang, Feng ; Piras, Bryan A. ; Xu, Yaqin ; O'Connor, Daniel M. ; Beyers, Ronald J. ; Epstein, Frederick H. ; Annex, Brian H. ; Hossack, John A. ; French, Brent A. / Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling. In: Journal of Gene Medicine. 2012 ; Vol. 14, No. 9-10. pp. 609-620.
@article{e1833102a2e5428e800697f1bf1f1419,
title = "Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling",
abstract = "Background: Adeno-associated virus serotype 9 (AAV9) vectors provide efficient and uniform gene expression to normal myocardium following systemic administration, with kinetics that approach steady-state within 2-3 weeks. However, as a result of the delayed onset of gene expression, AAV vectors have not previously been administered intravenously after reperfusion for post-infarct gene therapy applications. The present study evaluated the therapeutic potential of post-myocardial infarction gene delivery using intravenous AAV9. Methods: AAV9 vectors expressing firefly luciferase, enhanced green fluorescent protein (eGFP) or extracellular superoxide dismutase genes from the cardiac troponin-T (cTnT) promoter (AcTnTLuc, AcTnTeGFP, AcTnTEcSOD) were employed. AcTnTLuc was administered intravenously at 10 min and at 1, 2 and 3 days post-ischemia/reperfusion (IR), and the kinetics of luciferase expression were assessed with bioluminescence imaging. AcTnTeGFP was used to evaluate the distribution of eGFP expression. High-resolution echocardiography was used to evaluate the effects of AcTnTEcSOD on left ventricular (LV) remodeling when injected 10 min post-IR. Results: Compared to sham animals, luciferase expression at 2 days after vector administration was elevated by four-, 24-, 210- and 213-fold in groups injected at 10 min, 1 day, 2 days and 3 days post-IR, respectively. The expression of cTnT-driven eGFP was strongest in cardiomyocytes bordering the infarct zone. In the efficacy study of EcSOD, post-infarct LV end-systolic and end-diastolic volumes at days 14 and 28 were significantly smaller in the EcSOD group compared to the control. Conclusions: Systemic administration of AAV9 vectors after IR both elevates and accelerates gene expression that preferentially targets cardiomyocytes in the border zone with pharmacodynamics suitable for the attenuation of LV remodeling.",
keywords = "AAV, Cardiac gene therapy, Ischemia and reperfusion injury, LV remodeling, Post myocardial infarction gene delivery",
author = "Konkalmatt, {Prasad R.} and Feng Wang and Piras, {Bryan A.} and Yaqin Xu and O'Connor, {Daniel M.} and Beyers, {Ronald J.} and Epstein, {Frederick H.} and Annex, {Brian H.} and Hossack, {John A.} and French, {Brent A.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1002/jgm.2673",
language = "English (US)",
volume = "14",
pages = "609--620",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "9-10",

}

TY - JOUR

T1 - Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling

AU - Konkalmatt, Prasad R.

AU - Wang, Feng

AU - Piras, Bryan A.

AU - Xu, Yaqin

AU - O'Connor, Daniel M.

AU - Beyers, Ronald J.

AU - Epstein, Frederick H.

AU - Annex, Brian H.

AU - Hossack, John A.

AU - French, Brent A.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Background: Adeno-associated virus serotype 9 (AAV9) vectors provide efficient and uniform gene expression to normal myocardium following systemic administration, with kinetics that approach steady-state within 2-3 weeks. However, as a result of the delayed onset of gene expression, AAV vectors have not previously been administered intravenously after reperfusion for post-infarct gene therapy applications. The present study evaluated the therapeutic potential of post-myocardial infarction gene delivery using intravenous AAV9. Methods: AAV9 vectors expressing firefly luciferase, enhanced green fluorescent protein (eGFP) or extracellular superoxide dismutase genes from the cardiac troponin-T (cTnT) promoter (AcTnTLuc, AcTnTeGFP, AcTnTEcSOD) were employed. AcTnTLuc was administered intravenously at 10 min and at 1, 2 and 3 days post-ischemia/reperfusion (IR), and the kinetics of luciferase expression were assessed with bioluminescence imaging. AcTnTeGFP was used to evaluate the distribution of eGFP expression. High-resolution echocardiography was used to evaluate the effects of AcTnTEcSOD on left ventricular (LV) remodeling when injected 10 min post-IR. Results: Compared to sham animals, luciferase expression at 2 days after vector administration was elevated by four-, 24-, 210- and 213-fold in groups injected at 10 min, 1 day, 2 days and 3 days post-IR, respectively. The expression of cTnT-driven eGFP was strongest in cardiomyocytes bordering the infarct zone. In the efficacy study of EcSOD, post-infarct LV end-systolic and end-diastolic volumes at days 14 and 28 were significantly smaller in the EcSOD group compared to the control. Conclusions: Systemic administration of AAV9 vectors after IR both elevates and accelerates gene expression that preferentially targets cardiomyocytes in the border zone with pharmacodynamics suitable for the attenuation of LV remodeling.

AB - Background: Adeno-associated virus serotype 9 (AAV9) vectors provide efficient and uniform gene expression to normal myocardium following systemic administration, with kinetics that approach steady-state within 2-3 weeks. However, as a result of the delayed onset of gene expression, AAV vectors have not previously been administered intravenously after reperfusion for post-infarct gene therapy applications. The present study evaluated the therapeutic potential of post-myocardial infarction gene delivery using intravenous AAV9. Methods: AAV9 vectors expressing firefly luciferase, enhanced green fluorescent protein (eGFP) or extracellular superoxide dismutase genes from the cardiac troponin-T (cTnT) promoter (AcTnTLuc, AcTnTeGFP, AcTnTEcSOD) were employed. AcTnTLuc was administered intravenously at 10 min and at 1, 2 and 3 days post-ischemia/reperfusion (IR), and the kinetics of luciferase expression were assessed with bioluminescence imaging. AcTnTeGFP was used to evaluate the distribution of eGFP expression. High-resolution echocardiography was used to evaluate the effects of AcTnTEcSOD on left ventricular (LV) remodeling when injected 10 min post-IR. Results: Compared to sham animals, luciferase expression at 2 days after vector administration was elevated by four-, 24-, 210- and 213-fold in groups injected at 10 min, 1 day, 2 days and 3 days post-IR, respectively. The expression of cTnT-driven eGFP was strongest in cardiomyocytes bordering the infarct zone. In the efficacy study of EcSOD, post-infarct LV end-systolic and end-diastolic volumes at days 14 and 28 were significantly smaller in the EcSOD group compared to the control. Conclusions: Systemic administration of AAV9 vectors after IR both elevates and accelerates gene expression that preferentially targets cardiomyocytes in the border zone with pharmacodynamics suitable for the attenuation of LV remodeling.

KW - AAV

KW - Cardiac gene therapy

KW - Ischemia and reperfusion injury

KW - LV remodeling

KW - Post myocardial infarction gene delivery

UR - http://www.scopus.com/inward/record.url?scp=84868147722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868147722&partnerID=8YFLogxK

U2 - 10.1002/jgm.2673

DO - 10.1002/jgm.2673

M3 - Article

C2 - 23065925

AN - SCOPUS:84868147722

VL - 14

SP - 609

EP - 620

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 9-10

ER -